Concealing cellular defects in pluripotent stem cells

Trends in Cell Biology

Volumn 23, Issue 12, 2013, Pages 587-592

  Zhang, Weiqi ^a   Qu, Jing ^a,f   Suzuki, Keiichiro ^b   Liu, Guang Hui ^a,c,d   Belmonte, Juan Carlos Izpisua ^b,e  

^a INSTITUTE OF BIOPHYSICS   (China)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^d BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^e CENTER OF REGENERATIVE MEDICINE IN BARCELONA   (Spain)

^f INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Disease modeling; Pluripotent stem cell; Reprogramming

Indexed keywords

CELL AGING; CELL DAMAGE; CELL DIFFERENTIATION; CELL TRANSFORMATION; CYTOARCHITECTURE; EMBRYONIC STEM CELL; EPIGENETICS; HUMAN; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SENESCENCE; SOMATIC CELL; TRINUCLEOTIDE REPEAT;

DISEASE MODELING; PLURIPOTENT STEM CELL; REPROGRAMMING;

ANIMALS; CELL AGING; EPIGENESIS, GENETIC; HUMANS; MODELS, BIOLOGICAL; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELLS;

EID: 84888200046     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2013.07.001     Document Type: Review

References (50)

1. Gonzalez F., et al. Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat. Rev. Genet. 2011, 12:231-242.
2. Urbach A., et al. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010, 6:407-411.
3. Liu J., et al. Signaling defects in iPSC-derived fragile X premutation neurons. Hum. Mol. Genet. 2012, 21:3795-3805.
4. Sheridan S.D., et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS ONE 2011, 6:e26203.
5. Alisch R.S., et al. Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1 locus. BMC Med. Genet. 2013, 14:18.
6. Utikal J., et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J. Cell Sci. 2009, 122:3502-3510.
7. Hochedlinger K., et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004, 18:1875-1885.
8. Carette J.E., et al. Generation of iPSCs from cultured human malignant cells. Blood 2010, 115:4039-4042.
9. Choi S.M., et al. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood 2011, 118:1801-1805.
10. Kumano K., et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012, 119:6234-6242.
11. Hamada M., et al. Reprogramming to pluripotency can conceal somatic cell chromosomal instability. PLoS Genet. 2012, 8:e1002913.
12. Yang H., et al. Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. Cell 2012, 149:605-617.
13. Leeb M., Wutz A. Derivation of haploid embryonic stem cells from mouse embryos. Nature 2011, 479:131-134.
14. Elling U., et al. Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell 2011, 9:563-574.
15. Li W., et al. Androgenetic haploid embryonic stem cells produce live transgenic mice. Nature 2012, 490:407-411.
16. Noggle S., et al. Human oocytes reprogram somatic cells to a pluripotent state. Nature 2011, 478:70-75.
17. Ron-Bigger S., et al. Aberrant epigenetic silencing of tumor suppressor genes is reversed by direct reprogramming. Stem Cells 2010, 28:1349-1354.
18. Zhang X., et al. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2013, 32:2249-2260.
19. Pomp O., et al. Unexpected X chromosome skewing during culture and reprogramming of human somatic cells can be alleviated by exogenous telomerase. Cell Stem Cell 2011, 9:156-165.
20. Marchetto M.C., et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.
21. Cheung A.Y., et al. Isolation of MECP2-null Rett syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum. Mol. Genet. 2011, 20:2103-2115.
22. Ananiev G., et al. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model. PLoS ONE 2011, 6:e25255.
23. Larimore J., et al. MeCP2 regulates the synaptic expression of a Dysbindin-BLOC-1 network component in mouse brain and human induced pluripotent stem cell-derived neurons. PLoS ONE 2013, 8:e65069.
24. Kim K.Y., et al. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14169-14174.
25. Constantinescu D., et al. Lamin A/C expression is a marker of mouse and human embryonic stem cell differentiation. Stem Cells 2006, 24:177-185.
26. Li M., et al. Navigating the epigenetic landscape of pluripotent stem cells. Nat. Rev. Mol. Cell Biol. 2012, 13:524-535.
27. Liu G.H., et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011, 472:221-225.
28. Siu C.W., et al. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Aging (Albany NY) 2012, 4:803-822.
29. Xiong Z.M., et al. An inhibitory role of progerin in the gene induction network of adipocyte differentiation from iPS cells. Aging (Albany NY) 2013, 5:288-303.
30. Zhang J., et al. A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011, 8:31-45.
31. Kim Y., et al. Mouse B-type lamins are required for proper organogenesis but not by embryonic stem cells. Science 2011, 334:1706-1710.
32. Suhr S.T., et al. Mitochondrial rejuvenation after induced pluripotency. PLoS ONE 2010, 5:e14095.
33. Prigione A., et al. Mitochondrial-associated cell death mechanisms are reset to an embryonic-like state in aged donor-derived iPS cells harboring chromosomal aberrations. PLoS ONE 2011, 6:e27352.
34. Lapasset L., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev. 2011, 25:2248-2253.
35. Ho J.C., et al. Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging (Albany NY) 2011, 3:380-390.
36. Xiong Z.M., et al. An inhibitory role of progerin in the gene induction network of adipocyte differentiation from iPS cells. Aging (Albany NY) 2013, 5:288-303.
37. Batista L.F., et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 2011, 474:399-402.
38. Agarwal S., et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 2010, 464:292-296.
39. Marion R.M., et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 2009, 4:141-154.
40. Wang F., et al. Molecular insights into the heterogeneity of telomere reprogramming in induced pluripotent stem cells. Cell Res. 2012, 22:757-768.
41. Zhang W., et al. Evolution of iPSC disease models. Protein Cell 2012, 3:1-4.
42. Liu G.H., et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012, 491:603-607.
43. Liu G.H., et al. iPSC technology to study human aging and aging-related disorders. Curr. Opin. Cell Biol. 2012, 24:765-774.
44. Quarto N., et al. Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:215-220.
45. Soldner F., et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011, 146:318-331.
46. Liu G.H., et al. Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 2011, 8:688-694.
47. Liu G.H., et al. Cut and paste: restoring cellular function by gene correction. Cell Res. 2012, 22:283-284.
48. Zhang W., et al. Non-viral iPSCs: a safe way for therapy?. Protein Cell 2012, 3:241-245.
49. Liu W., et al. Reevaluation of the safety of induced pluripotent stem cells: a call from somatic mosaicism. Protein Cell 2013, 4:83-85.
50. Chamberlain S.J., et al. Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells 2008, 26:1496-1505.